All Updates

All Updates

icon
Filter
Partnerships
BioStrand collaborates with PGxAI to develop and commercialize patented foundation AI model 'LENSai'
Precision Medicine
Jun 25, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Precision Medicine

Precision Medicine

Jun 25, 2024

BioStrand collaborates with PGxAI to develop and commercialize patented foundation AI model 'LENSai'

Partnerships

  • BioStrand has announced its collaboration with PGxAI to develop and commercialize its patented foundation AI model, LENSai.

  • As part of the partnership, PGxAI will support the commercial rollout of the LENSai Application Programming Interface (API) by expanding product features and market reach. This collaboration addresses problems when analyzing and interpreting large amounts of genetic information. LENSai will be an advanced tool that processes LLMs, research, and patient data, enabling custom treatments to improve patient outcomes. 

  • BioStrand, a subsidiary of ImmunoPrecise Antibodies (IPA), is a Belgium-based biotechnology company specializing in genomic analysis and biotherapeutic discovery. It has developed a novel methodology to identify similarities and variations in genetic data. The company's proprietary HYFT technology enables the detection of unique fingerprints in biological sequences, facilitating advanced genomic research and precision medicine applications. BioStrand's offerings include AI-driven tools for sequence retrieval, drug development, and agricultural biotech.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.